A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

NCT06118515 | Recruiting Phase 1 FDA Drug

• 2 other identifiers: 21-00275U54AI150225-05
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 10

Brief Summary

This is a Phase 1 single-arm open-label study of letermovir in neonates with symptomatic congenital Cytomegalovirus (CMV) disease. There will be two groups enrolled. Group 1 will be comprised of 4 subjects. Following documentation study inclusion and signing of informed consent, Group 1 subjects will receive one dose of oral letermovir (Study Day 0), using the dose bands. A full pharmacokinetics (PK) profile will then be obtained over the next 24 hours, and blood specimens will be shipped immediately to the University of Alabama at Birmingham (UAB) Pharmacokinetic Lab and processed in real time. Within = 7 days, pharmacokinetics (PK) results will be conveyed to the study site. If the Area Under the Curve (AUC24) is =100,000 ngxhr/mL (see footnote a in Table 1), the subject will initiate a 14-day course of once-daily oral letermovir at the same dose as utilized on Dose Finding Day. This duration of letermovir therapy was selected based upon our earlier observation in this population that patients with symptomatic congenital Cytomegalovirus (CMV) disease who achieve viral suppression to =2.5 log by day 14 of valganciclovir therapy and then maintain it over the next 4 months are statistically more likely to have improved hearing across the first two years of life (22). If the observed letermovir exposure of the subject is \> 100,000 ngxhr/mL, the once-daily oral letermovir dose that will be used will be adjusted down in 2.5 mg increments. Oral valganciclovir (16 mg/kg/dose BID) will begin within the first month of life, as standard of care; initiation of valganciclovir can be concomitant with or prior to initiation of the 14-day course of letermovir (but will not start before obtaining the pharmacokinetics (PK) specimens following the single dose of letermovir on the Dose Finding Day). This is similar to the intensification approach that has been evaluated in the management of patients infected with human immunodeficiency virus (23-25). The day that the 14-day course of letermovir begins for Group 1 subjects will be known as Study Day 1. Serial blood samples will be obtained on Study Days 1, 5, 10, and 14 for safety chemistry and hematology labs and for Cytomegalovirus (CMV) viral loads. Cytomegalovirus (CMV) viral load will be followed as well on Study Days 21 and 42 to assess for rebound in Cytomegalovirus (CMV) following cessation of letermovir treatment on Study Day 14. Saliva and urine viral loads will be followed at these timepoint as well. Full pharmacokinetics (PK) profiles for both letermovir and ganciclovir will be obtained on Study Day 10. In addition, sparse pharmacokinetics (PK) sampling will be obtained on Study Days 1, 5, and 14. Adverse events will be assessed at each study visit during treatment, and at Study Days 21 and 42 (4 weeks after the last study drug dose). Subjects then will continue on oral valganciclovir as routine clinical care to complete an anticipated 6 month duration of total therapy. The primary Objective is to determine the systemic exposure (AUC24) of letermovir following administration of oral letermovir granules in infants with symptomatic congenital CMV disease.

Conditions

Congenital Cytomegalovirus Infection

Keywords

Congenital Cytomegalovirus Disease; Infants; Letermovir; Pharmacokinetic; Phase 1

Outcome Measures

Primary Outcomes (1)

• Plasma letermovir area under the curve (AUC24) concentrations

  Determined using the linear-log trapezoidal rule. In addition, a population PK analysis may be conducted at the end of the study.

  Through Day 14

Secondary Outcomes (8)

• Frequency of serious adverse events (SAEs)

  Through Day 14

• Frequency of grade 3 adverse events (AEs)

  Through Day 14

• Frequency of grade 4 adverse events (AEs)

  Through Day 14

• Plasma letermovir clearance (CL)

  Through Day 14

• Plasma letermovir half-life (T1/2)

  Through Day 14

Study Arms (2)

Group 1

EXPERIMENTAL

Neonates (\</= 83 days) with symptomatic congenital Cytomegalovirus (CMV) disease will receive one dose of oral letermovir, using weight dose banding. All subjects also will receive valganciclovir as standard of care. A dose safety evaluation will occur to ensure the safety data support subjects proceeding. If the observed letermovir exposure is \</= 100,000 ngxhr/mL, the subject will initiate a 14-day course of once-daily oral letermovir at the same dose as utilized on the Dose Finding Day. If the observed letermovir exposure of the subject is \> 100,000 ngxhr/mL, the once-daily oral letermovir dose that will be used will be adjusted down in 2.5 mg increments from the dose utilized on the Dose Finding Day. N = 4

Drug: Letermovir

Group 2

EXPERIMENTAL

Neonates (\</= 90 days) with symptomatic congenital Cytomegalovirus (CMV) disease will initiate a 14-day course of once-daily oral letermovir, using weight dose banding. All subjects also will receive valganciclovir as standard of care. A dose escalation safety evaluation will occur to ensure the safety data support subjects proceeding. If the median of observed letermovir exposures of subjects in Group 1 is below 34,400 ngxhr/mL (or above 100,000 ngxhr/mL), then the subjects enrolled in Group 2 will receive once-daily oral letermovir at a dose that has been adjusted upward (or downward) in 2.5 mg increments. N=8

Drug: Letermovir

Interventions

Letermovir DRUG

Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.

Group 1; Group 2

Eligibility Criteria

• Age: 0 Days - 90 Days
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Signed informed consent from parent(s) or legal guardian(s)
• Cytomegalovirus (CMV) confirmation by culture, shell vial, or Polymerase Chain Reaction (PCR) tests from a specimen obtained at \</= 30 days of life from saliva, blood, or urine
• Symptomatic congenital CMV disease\*
• Age at study enrollment:
• \</= 83 days for Group 1 subjects\*\*
• \</= 90 days for Group 2 subjects
• Weight at study enrollment 2.6 kg to \< 8.0 kg
• Gestational age \>/= 32 weeks at birth
• Intention by patient's physician to clinically treat infant with oral valganciclovir for 6 months for symptomatic congenital CMV disease
• Manifested by one or more of the following: thrombocytopenia; petechiae; hepatomegaly; splenomegaly; intrauterine growth restriction; hepatitis; or Central Nervous System (CNS) involvement such as microcephaly, radiographic abnormalities indicative of CMV CNS disease, abnormal cerebrospinal fluid (CSF) indices for age, chorioretinitis, hearing deficits as detected by formal brainstem evoked response, and/or positive CMV Polymerase Chain Reaction (PCR) from CSF \*\*Group 1 subjects must enroll and receive the Dose Finding Day dose of letermovir on or before 83 days of life so that oral valganciclovir can be started prior to 12 weeks 6 days (which is 90 days) of life, as is standard of care. For this study, the date of birth is counted as day of life 0

You may not qualify if:

• Imminent demise
• Infants known to be born to women who are HIV positive (but HIV testing is not required for study entry)
• Current receipt of other investigational drugs
• Grade 3 or 4 alanine aminotransferase (ALT) utilizing Division of AIDS (DAIDS) Toxicity Table
• Grade 3 or 4 total bilirubin utilizing DAIDS Toxicity Table
• Gastrointestinal abnormality which might preclude absorption of an oral medication (e.g., a history of necrotizing enterocolitis)
• Anticipated concomitant administration of carbamazepine (Tegretol), nafcillin, phenobarbital, or phenytoin (Dilantin) during the period of study drug administration

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (10)

Children's of Alabama Child Health Research Unit (CHRU)

Birmingham, Alabama, 35233-0011, United States

RECRUITING

Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease

Washington D.C., District of Columbia, 20010-2916, United States

WITHDRAWN

Emory University School of Medicine

Atlanta, Georgia, 30322-1014, United States

RECRUITING

University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases

Louisville, Kentucky, 40202, United States

WITHDRAWN

Louisiana State University Health Shreveport - Infectious Diseases

Shreveport, Louisiana, 71101, United States

WITHDRAWN

University of Minnesota - Pediatric Infectious Disease

Minneapolis, Minnesota, 55454, United States

WITHDRAWN

SUNY Upstate Medical University Hospital - Pediatrics

Syracuse, New York, 13210-2342, United States

WITHDRAWN

Nationwide Children's Hosp.-Neonatology-Ctr. for Perinatal Rsrch.

Columbus, Ohio, 43205-2664, United States

WITHDRAWN

University of Texas Southwestern Medical Center - Pediatrics

Dallas, Texas, 75390-9063, United States

WITHDRAWN

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

RECRUITING

MeSH Terms

Conditions

Cytomegalovirus Infections

Interventions

letermovir

Condition Hierarchy (Ancestors)

Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections

Central Study Contacts

David W. Kimberlin

CONTACT

12056382530; dkimberlin@peds.uab.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 1, 2023
• First Posted: November 7, 2023
• Study Start: February 19, 2025
• Primary Completion (Estimated): May 15, 2026
• Study Completion (Estimated): August 31, 2026
• Last Updated: April 13, 2026

Record last verified: 2025-07-18

Locations

US (10)